https://www.thebodypro.com/category/dolutegravir-tivicay/tag/women

The Latest

Ricardo Diaz, M.D. (top left) shares findings regarding a potential new HIV remission case in a virtual press conference during the 23rd International AIDS Conference on July 7, 2020.

HIV Clinical Research Highlights From AIDS 2020, the 23rd International AIDS Conference

COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.

By Myles Helfand
pregnant belly

Tempering Previous Concerns, Study Finds Dolutegravir Safest HIV Treatment During Pregnancy

New data shows the drug is not more likely to cause birth defects.

By Sony Salzman
aging face

This Week in HIV Research: Playing Catchup on the Aging Front

March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.

By Barbara Jungwirth and Myles Helfand
men on beach

This Week in HIV Research: Do You Believe in U=U?

Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.

By Barbara Jungwirth and Myles Helfand
three human skeleton models doing "see no evil, hear no evil, speak no evil"

This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

By Barbara Jungwirth and Myles Helfand
pregnant stomach

This Week in HIV Research: Pregnancy Findings That Aren't About Dolutegravir

Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.

By Barbara Jungwirth and Myles Helfand
Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

By Sony Salzman
Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

By Sony Salzman
Dolutegravir Preconception Signal: Time Is Up for Shoddy Surveillance Img

Dolutegravir Preconception Signal: Time Is Up for Shoddy Surveillance

"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.

By Polly Clayden for HIV i-Base
Integrase Inhibitors and Their Effectiveness and Safety in Women Img

Integrase Inhibitors and Their Effectiveness and Safety in Women

Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange